The purpose of this study is to see whether HLA-mismatched donor cells infusion with chemotherapy (microtransplantation，MST) could increase complete remission (CR) and improve survival in older patients with acute myeloid leukemia (AML)，the investigators conducted a prospective, multicenter clinical trial of HLA-mismatched MST to estimate outcomes and toxicities.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
150
HLA mismatched donor mobilized prepheral stem cell infusion
Affiliated Hospital of Academy of Military Medical Sciences ,
Beijing, Beijing Municipality, China
Graft versus host disease
Time frame: 1 month
overall survival
Time frame: 2 years
leukemia free survival
Time frame: 2 years
complete remission rate
Time frame: 2 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.